GSK Expands Respiratory Portfolio through $1.4 Billion Aiolos Bio Deal
-
Drug News
GSK Expands Respiratory Portfolio through $1.4 Billion Aiolos Bio Deal
British pharmaceutical giant GlaxoSmithKline (GSK) announced a strategic move to bolster its respiratory diseases portfolio with the acquisition of Aiolos…
Read More »
